Pharma M&A Surge Eases Biotech VC Exit Struggles
Big pharmaceutical companies circling mature drug candidates as they seek to fill a revenue hole of more than $200 billion — created by a looming patent cliff — might provide respite...To view the full article, register now.
Already a subscriber? Click here to view full article